IMMUNOVIA JOINS MORE THAN 40 GLOBAL PANCREATIC CANCER ORGANIZATIONS AT INAGURAL MEETING
LUND, Sweden – (May 9, 2016) The first-ever World Pancreatic Cancer Coalition (WPCC) will gather for its inaugural meeting in Orlando, Fla., on May 11, 2016, bringing together more than 60 individuals representing 40 pancreatic cancer advocacy groups from around the globe. The Coalitions’ goal is to drive transformational change for those affected by pancreatic cancer.
“By standing in unison, we hope to save more lives and create a brighter future for the disease with the lowest survival rate of any major cancer,” said Julie Fleshman, JD, MBA, chair of the WPCC and president and CEO of the Pancreatic Cancer Action Network.
Around the world, pancreatic cancer is the seventh most common cause of cancer-related death in men and women combined.1 Only 2 to 10 percent of those diagnosed globally survive five years.2
Three years ago, in 2013, pancreatic cancer patient advocacy organizations from around the world, with founding sponsor Celgene Corporation, began discussions about how best to support each other’s efforts while raising global awareness for the deadly disease.
“We realized that by working collaboratively, we could have a much greater impact than the sum of our parts,” said Mats Grahn, CEO, Immunovia. “We swiftly moved to action this year to become part of the inaugural meeting of the World Pancreatic Cancer Coalition (WPCC), which is a fantastic global awareness-raising initiative.”
The World Pancreatic Cancer Coalition will oversee the annual World Pancreatic Cancer Day, which was first held in Nov. 2014 and is observed and celebrated from the United States to Europe and from Asia to Australia.
November has long been recognized as Pancreatic Cancer Awareness Month. This year, World Pancreatic Cancer Day will be held on Nov. 17.
The one-day event aims to raise awareness about the disease, but also to spread the word that with more research funding and more people taking action, pancreatic cancer survival rates can, and will, improve.
For additional information on pancreatic cancer, the World Pancreatic Cancer Coalition and its members, please visit worldpancreaticcancercoalition.org.
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
About the World Pancreatic Cancer Coalition
The World Pancreatic Cancer Coalition is an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. Through global collaboration, the Coalition raises awareness of pancreatic cancer by strengthening the efforts of participating member organizations. And each November, Pancreatic Cancer Awareness Month, Coalition members unite on World Pancreatic Cancer Day to draw attention to pancreatic cancer and highlight the need for greater awareness, funding and research.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed 03/14/16.American Cancer Society. Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society; 2011.